Methadone in Post-Herpetic Neuralgia Pain (NPH)

This study has been completed.
Information provided by (Responsible Party):
Daniel Ciampi Araujo de Andrade, University of Sao Paulo Identifier:
First received: December 11, 2012
Last updated: March 14, 2013
Last verified: March 2013

Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.

Condition Intervention Phase
Post-herpetic Neuralgia
Drug: Methadone
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Methadone in Post-Herpetic Neuralgia Pain

Resource links provided by NLM:

Further study details as provided by University of Sao Paulo:

Primary Outcome Measures:
  • Change in baseline Pain [ Time Frame: baseline (visit inclusion) and three moths latter ] [ Designated as safety issue: No ]
    Assessing by verbal analog scale (VAS)

Enrollment: 10
Study Start Date: January 1998
Study Completion Date: March 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Methadone
in this arm patients will take methadone 5mg.
Drug: Methadone
patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
Experimental: Placebo
in this arm patients will take placebo pills.
Drug: Placebo
patients with post-herpetic neuralgia take placebo to treat the pain symptoms.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with chronic (>6 months) symptomatic PHN
  • with visual analogical scale >40/100mm
  • use of first and second line drugs (tricyclic antidepressants, venlafaxine and gabapentinoids)

Exclusion Criteria:

  • Don't full the criteria above
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided by University of Sao Paulo

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Daniel Ciampi Araujo de Andrade, MD, PhD, University of Sao Paulo Identifier: NCT01752699     History of Changes
Other Study ID Numbers: NPH
Study First Received: December 11, 2012
Last Updated: March 14, 2013
Health Authority: Brazil: Ethics Committee

Keywords provided by University of Sao Paulo:
neuropathic pain,
post-herpetic neuralgia,

Additional relevant MeSH terms:
Neuralgia, Postherpetic
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Diseases
Peripheral Nervous System Diseases
Signs and Symptoms
Analgesics, Opioid
Antitussive Agents
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Sensory System Agents
Therapeutic Uses processed this record on October 20, 2014